Boston Medical Center (2012) Bortezomib and dexamethasone followed by high-dose melphalan and stem cell transplantation for primary (AL) amyloidosis. http://clinicaltrials.gov/ct2/show/NCT01083316

has been cited by the following article:

• TITLE: On the road: Clinical trials with stem cell extended to non-hematologic disease

  AUTHORS: Jinyang Yu, Yanqiu Yu

  KEYWORDS: Stem Cell; Clinical Trials; Hematologic Disease; Non-Hematologic Disease

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.2, February 28, 2013

  ABSTRACT: Increasing evidence in scientific journals declares that stem cell can be used in human medicine for therapeutic purposes. We reviewed the lated literature on clinical trials conducted with stem cells. The main information was offered by http://www.ClinicalTrials.gov. These clinical trials cover almost all human diseases, from hematologic diseases to non-hematologic diseases including Interventional trials and observational trials. In conclusion, at present, the clinical trials with stem cells have been extending to almost all human diseases. Optimal medicinal effect reported in some non-hematologic diseases is pushing the advance of stem cells therapy